# Milestone 2 Independent Review — F-EX-M2-13

- Reviewer: independent GPT-5.5 medium reviewer
- Plan: v13
- Reviewed baseline commit: `9c736bc029f4da16e5932a16b3f8bdf49dba57f1`, plus the current dirty/untracked worktree
- Verdict: **PASS**

| AC | Verdict | Evidence |
| --- | --- | --- |
| AC-01 | PASS | Authorized treatment admission is hash-validated, status-gated, host/profile-bound, and rebound into a separate authorized batch manifest. |
| AC-07 | PASS | Stale/mismatched host facts, profile mismatch, run-ID mismatch, and prepared-only launch fail closed. |
| AC-08 | PASS | Core validates authorized treatment admission before execution and passes it to phase invocation; queue/monitor contract tests pass. |

Reviewer-owned verification:

```bash
REPO_HOST=/data-1/code/verl /data-1/verl07/run_train.sh python -m pytest -q tests/experiment_workflow/test_stage123_control_reuse.py tests/experiment_workflow/test_manifest_queue_monitor_contract.py
```

Result: `15 passed in 17.65s`.

`F-EX-M2-13` passes: authorization produces a separate
`authorized-treatment-batch-manifest.json`, binds its item to the post-authorization
admission SHA and decision ID, leaves the prepared template byte-for-byte unchanged,
and the focused regression proves `batch-validate` accepts the authorized manifest.

No blocking defect or contract contradiction was found. The reviewer deferred one
non-blocking suggestion to add a full successful `authorize-treatment` CLI test with
mocked host probes; the live fresh authorization before launch provides operational
evidence for the current Goal.
